IntegraGen Licenses Biomarkers to Develop Dx for Liver Cancer | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French molecular diagnostics outfit IntegraGen, the French National Institute for Health and Medical Research (INSERM), and its technology transfer subsidiary, INSERM Transfert, announced on Tuesday an agreement granting IntegraGen an exclusive worldwide option to license a portfolio of biomarkers for hepatocellular carcinoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.